GlaxoSmithKline plc (LON:GSK) insider Simon Dingemans bought 9 shares of GlaxoSmithKline stock in a transaction that occurred on Tuesday, October 9th. The shares were acquired at an average price of GBX 1,475 ($19.27) per share, with a total value of £132.75 ($173.46).
GSK opened at GBX 1,429.40 ($18.68) on Friday. GlaxoSmithKline plc has a 12-month low of GBX 1,235.20 ($16.14) and a 12-month high of GBX 1,724.50 ($22.53).
The company also recently disclosed a dividend, which was paid on Thursday, October 11th. Stockholders of record on Thursday, August 9th were issued a GBX 19 ($0.25) dividend. This represents a dividend yield of 1.23%. The ex-dividend date was Thursday, August 9th.
Several equities analysts recently commented on GSK shares. Deutsche Bank set a GBX 1,525 ($19.93) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Tuesday, July 31st. Liberum Capital restated a “buy” rating on shares of GlaxoSmithKline in a research report on Monday, July 23rd. Societe Generale set a GBX 1,000 ($13.07) target price on GlaxoSmithKline and gave the stock a “sell” rating in a research report on Monday, September 10th. JPMorgan Chase & Co. set a GBX 1,600 ($20.91) target price on GlaxoSmithKline and gave the stock a “neutral” rating in a research report on Tuesday, September 18th. Finally, UBS Group restated a “buy” rating and set a GBX 1,700 ($22.21) target price on shares of GlaxoSmithKline in a research report on Thursday, September 27th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating and ten have given a buy rating to the company. GlaxoSmithKline presently has a consensus rating of “Hold” and an average price target of GBX 1,533.55 ($20.04).
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: Why Dividend Stocks May Be Right for You
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.